S&P 500   3,092.41 (-0.05%)
DOW   27,749.57 (-0.12%)
QQQ   201.13 (-0.23%)
CGC   15.62 (-15.57%)
BABA   181.95 (-0.29%)
GE   11.29 (+0.00%)
T   38.77 (-1.00%)
ACB   3.19 (-10.14%)
BAC   32.54 (-0.79%)
DIS   147.85 (-0.58%)
S&P 500   3,092.41 (-0.05%)
DOW   27,749.57 (-0.12%)
QQQ   201.13 (-0.23%)
CGC   15.62 (-15.57%)
BABA   181.95 (-0.29%)
GE   11.29 (+0.00%)
T   38.77 (-1.00%)
ACB   3.19 (-10.14%)
BAC   32.54 (-0.79%)
DIS   147.85 (-0.58%)
S&P 500   3,092.41 (-0.05%)
DOW   27,749.57 (-0.12%)
QQQ   201.13 (-0.23%)
CGC   15.62 (-15.57%)
BABA   181.95 (-0.29%)
GE   11.29 (+0.00%)
T   38.77 (-1.00%)
ACB   3.19 (-10.14%)
BAC   32.54 (-0.79%)
DIS   147.85 (-0.58%)
S&P 500   3,092.41 (-0.05%)
DOW   27,749.57 (-0.12%)
QQQ   201.13 (-0.23%)
CGC   15.62 (-15.57%)
BABA   181.95 (-0.29%)
GE   11.29 (+0.00%)
T   38.77 (-1.00%)
ACB   3.19 (-10.14%)
BAC   32.54 (-0.79%)
DIS   147.85 (-0.58%)
Log in

Navidea Biopharmaceuticals Stock Price, Forecast & Analysis (NYSEAMERICAN:NAVB)

$0.72
+0.04 (+5.89 %)
(As of 11/14/2019 01:53 PM ET)
Today's Range
$0.64
Now: $0.72
$0.72
50-Day Range N/A
52-Week Range
$0.49
Now: $0.72
$4.40
Volume97,933 shs
Average Volume296,027 shs
Market Capitalization$7.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSEAMERICAN:NAVB
Previous SymbolNYSEMKT:NAVB
CUSIP63937X10
Phone+1-614-7937500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Market Cap$7.23 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.


Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.17). The biopharmaceutical company had revenue of $0.24 million for the quarter. View Navidea Biopharmaceuticals' Earnings History.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals.

What price target have analysts set for NAVB?

1 brokerages have issued 12-month price targets for Navidea Biopharmaceuticals' stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Navidea Biopharmaceuticals' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 198.5% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals.

What is the consensus analysts' recommendation for Navidea Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

News articles about NAVB stock have trended somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Navidea Biopharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Navidea Biopharmaceuticals.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,220,000 shares, an increase of 85.7% from the September 30th total of 656,900 shares. Based on an average daily volume of 546,900 shares, the short-interest ratio is presently 2.2 days. Approximately 10.5% of the shares of the company are sold short. View Navidea Biopharmaceuticals' Current Options Chain.

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:
  • Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 67)
  • Ms. Sharon Correia, Sr. Director of Corp. Communications

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.67.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $6.74 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is http://www.navidea.com/.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel